Adriamycin 50 mg Na Uy - Tiếng Na Uy - Statens legemiddelverk

adriamycin 50 mg

pfizer as - doksorubicinhydroklorid - pulver til injeksjonsvæske, oppløsning - 50 mg

Dalacin 150 mg/ ml Na Uy - Tiếng Na Uy - Statens legemiddelverk

dalacin 150 mg/ ml

pfizer as - klindamycinfosfat - injeksjonsvæske, oppløsning - 150 mg/ ml

Dalacin 15 mg/ ml Na Uy - Tiếng Na Uy - Statens legemiddelverk

dalacin 15 mg/ ml

pfizer as - klindamycinpalmitathydroklorid - granulat til mikstur, oppløsning - 15 mg/ ml

Dalacin 150 mg Na Uy - Tiếng Na Uy - Statens legemiddelverk

dalacin 150 mg

pfizer as - klindamycinhydroklorid - kapsel, hard - 150 mg

Dalacin 300 mg Na Uy - Tiếng Na Uy - Statens legemiddelverk

dalacin 300 mg

pfizer as - klindamycinhydroklorid - kapsel, hard - 300 mg

Sobril 25 mg Na Uy - Tiếng Na Uy - Statens legemiddelverk

sobril 25 mg

pfizer as - oksazepam - tablett - 25 mg

Sobril 10 mg Na Uy - Tiếng Na Uy - Statens legemiddelverk

sobril 10 mg

pfizer as - oksazepam - tablett - 10 mg

Sobril 15 mg Na Uy - Tiếng Na Uy - Statens legemiddelverk

sobril 15 mg

pfizer as - oksazepam - tablett - 15 mg

Vfend Liên Minh Châu Âu - Tiếng Na Uy - EMA (European Medicines Agency)

vfend

pfizer europe ma eeig - vorikonazol - candidiasis; mycoses; aspergillosis - antimykotika for systemisk bruk - vorikonazol, er et bredspektret, triazole antifungal agent og er angitt i voksne og barn i alderen 2 år og over som følger:behandling av invasive aspergillosis;behandling av i candidaemianon-neutropenic pasienter, behandling av fluconazole motstandsdyktig mot alvorlige invasive candida-infeksjoner (inkludert c. krusei);behandling av alvorlige fungal infeksjoner forårsaket av scedosporium spp. og fusarium spp. vfend bør gis i hovedsak til pasienter med progressiv, muligens livstruende infeksjoner. profylakse av invasive soppinfeksjoner i høy risiko allogen blodkreft stamcelletransplantasjon (hsct) mottakere.

Xeljanz Liên Minh Châu Âu - Tiếng Na Uy - EMA (European Medicines Agency)

xeljanz

pfizer europe ma eeig - tofacitinib - leddgikt, reumatoid - immunsuppressive - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 og 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.